SELLAS Life Sciences (SLS) Current Leases (2010 - 2026)
SELLAS Life Sciences (SLS) reported Current Leases of $562000.0 for Q1 2026, little changed year-over-year from $561000.0 in Q1 2025, and up 3.31% quarter-over-quarter from $544000.0 in Q4 2025.
SELLAS Life Sciences (SLS) Current Leases (2010 - 2026) Analysis & Trends
SELLAS Life Sciences (SLS) has 13 years of Current Leases data on file, last reported at $562000.0 in Q1 2026.
- Current Leases for Q1 2026 came in at $562000.0, changed 0.18% year-over-year; the trailing twelve-month figure through Mar 2026 was $562000.0 (changed 0.18% YoY), and the FY2025 annual result was $544000.0, changed 0.0% from the prior year.
- Current Leases rose to $562000.0 in Q1 2026 per SLS's latest filing, from $544000.0 in the prior quarter.
- Over five years, Current Leases peaked at $599000.0 in Q3 2025 and troughed at $325000.0 in Q1 2022.
- A 5-year average of $480294.1 and a median of $488000.0 in 2024 frame the typical range for Current Leases.
- The sharpest annual moves came in 2022 and 2025: Current Leases soared 87.88% in 2022, then changed 0.0% in 2025.
- A 5-year view of Current Leases shows it stood at $372000.0 in 2022, then advanced by 19.89% to $446000.0 in 2023, then rose by 21.97% to $544000.0 in 2024, then changed by 0.0% to $544000.0 in 2025, then grew by 3.31% to $562000.0 in 2026.
- Business Quant data shows SLS's Current Leases at $562000.0 in Q1 2026, $544000.0 in Q4 2025, and $599000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 42,980.09 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 83,991.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 7.40 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | SELLAS Life Sciences | 1.39 Bn | 1.39 Bn | - | 562,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 562,000.00 |
| Dec 31, 2025 | 544,000.00 |
| Sep 30, 2025 | 599,000.00 |
| Jun 30, 2025 | 580,000.00 |
| Mar 31, 2025 | 561,000.00 |
| Dec 31, 2024 | 544,000.00 |
| Sep 30, 2024 | 576,000.00 |
| Jun 30, 2024 | 531,000.00 |
| Mar 31, 2024 | 488,000.00 |
| Dec 31, 2023 | 446,000.00 |
| Sep 30, 2023 | 466,000.00 |
| Jun 30, 2023 | 447,000.00 |
| Mar 31, 2023 | 427,000.00 |
| Dec 31, 2022 | 372,000.00 |
| Sep 30, 2022 | 356,000.00 |
| Jun 30, 2022 | 341,000.00 |
| Mar 31, 2022 | 325,000.00 |
| Dec 31, 2021 | 198,000.00 |
| Sep 30, 2021 | 190,000.00 |
| Jun 30, 2021 | 182,000.00 |